Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Goey, Andrew K L et al., 2014
Among several radiolabel types, fluorine-18 is one of the most favorable radioisotopes for nuclear medicine imaging owing to its low positron emission energy and potential for high resolution and wide use in todays clinical settings 16,18
The Obesity Cohort Produced One of the Strongest Signals Among patients with breast cancer and obesity, GLP-1 receptor agonist use was associated with a substantially lower hazard of all-cause mortality compared with nonuse
Consult a healthcare provider if you experience persistent side effects.
What to do if you experience hair loss on semaglutide If you're noticing increased hair shedding while on semaglutide, there are several steps you can take to support hair regrowth and minimize further loss
Eligibility requirements for the GLP-1 Bridge Program include: Age 18 or older Enrollment in a Medicare Part D or Medicare Advantage Prescription Drug (MA-PD) plan One of the following BMI and health condition combinations: BMI 35 (regardless of other health conditions) BMI 30 with at least one of the following: heart failure with preserved ejection fraction (HFpEF), hypertension, or chronic kidney disease (CKD) BMI 27 with a history of pre-diabetes, myocardial infarction, stroke, or peripheral artery disease (PAD) The program covers the following GLP-1 receptor agonists: Foundayo (orforglipron) tablet, all dose strengths and formulations Wegovy (semaglutide) injections and tablets, all dose strengths and formulations Zepbound (tirzepatide) injections, only when prescribed as the KwikPen (single-dose vials and other single-dose pen formats are excluded) All prescriptions require prior authorization through Humana, which oversees clinical review to ensure adherence to the program's strict medical-necessity guidelines
